Clinical study on insulin aspart in treatment of gestational diabetes mellitus

Objective To explore the clinical effect of insulin aspart in the treatment of gestational diabetes mellitus(GDM). MethodsNewly diagnosed patients with GDM(136 cases) in Zhongshan Hospital, Fudan University from April 2010 to August 2013 were randomly divided into control and treatment groups, and each group had 68 cases. The patients in the control group were sc administered with Isophane Protamine Biosynthetic Human Insulin Injection, while the patients in the treatment group were sc administered with Insulin Aspart 30 Injection before eating. Two groups of patients were followed up, and their blood sugar, inflammatory factors, and outcomes of maternal and neonatal in two groups were compared. Results After treatment, FPG, 2 h PG, Hb A1 C, and C peptide of two groups were significantly improved, and the difference was statistically significant in the same group before and after treatment(P 0.01). After treatment, FPG, 2 h PG, and Hb A1 C in treatment group were lower than those in the control group, while C peptide at 0.5 h and 2 h after meal in treatment group were higher than those in the control group, and there were differences between the two groups(P 0.05, 0.01). Blood glucose standard time, daily dosage of insulin, and hypoglycemia incidence in the treatment group were lower than those in the control group, and there were differences between the two groups(P 0.05). After treatment, CRP, IL-6, and PTX-3 in two groups were significantly reduced, and the difference was statistically significant in the same group before and after treatment(P 0.01). After treatment, the indicators in the treatment group were lower than those in the control group, and there were differences between the two groups(P 0.01). And outcomes of maternal and neonatal in two groups had no statistical significance, and patients in two groups did not appear serious adverse reactions. Conclusion Insulin aspart has the good clinical effect in the treatment of GDM, and can reduce drug and blood glucose standard time, while can improve inflammatory symptoms of GDM, which is worth clinical promotion.